The report is available in English with a French summary - KCE
The report is available in English with a French summary - KCE
The report is available in English with a French summary - KCE
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>KCE</strong> Reports 120 Plasma 1<br />
Scientific <strong>summary</strong><br />
Table of contents<br />
SCIENTIFIC SUMMARY ........................................................................................................... 1<br />
GLOSSARY ................................................................................................................................. 3<br />
1 INTRODUCTION ............................................................................................................ 5<br />
1.1 CONTEXT ..................................................................................................................................................... 5<br />
1.2 RESEARCH QUESTIONS ........................................................................................................................... 5<br />
2 SUPPLY OF PLASMA DERIVATIVES .......................................................................... 6<br />
2.1 COLLECTION OF PLASMA ...................................................................................................................... 6<br />
2.1.1 Legal and ethical framework .......................................................................................................... 6<br />
2.1.2 Plasma collection <strong>in</strong> Belgium ........................................................................................................ 12<br />
2.1.3 Plasma collection <strong>in</strong> other countries .......................................................................................... 22<br />
2.2 TRANSFORMATION OF PLASMA INTO PLASMA DERIVATIVES ............................................... 29<br />
2.2.1 Quick overview of fractionation process .................................................................................. 29<br />
2.2.2 <strong>The</strong> worldwide supply of plasma products .............................................................................. 32<br />
2.2.3 <strong>The</strong> supply of plasma stable derivatives <strong>in</strong> Belgium ................................................................. 34<br />
2.3 LIMITATIONS ............................................................................................................................................. 39<br />
3 DEMAND FOR PLASMA DERIVATIVES: THE CASE OF IMMUNOGLOBULINS<br />
.......................................................................................................................................... 40<br />
3.1 USE OF PLASMA DERIVATIVES IN BELGIUM .................................................................................... 40<br />
3.1.1 Methods ............................................................................................................................................ 40<br />
3.1.2 Results .............................................................................................................................................. 40<br />
3.1.3 <strong>The</strong> case of immunoglobul<strong>in</strong>s ...................................................................................................... 42<br />
3.2 INDICATIONS FOR IMMUNOGLOBULINS ...................................................................................... 43<br />
3.2.1 Recommendations for the use of immunoglobul<strong>in</strong>s................................................................ 43<br />
3.2.2 Evidence review on immunoglobul<strong>in</strong> effectiveness ................................................................. 49<br />
3.3 CONSUMPTION OF IMMUNOGLOBULINS ..................................................................................... 70<br />
3.3.1 Consumption <strong>in</strong> other countries ................................................................................................ 70<br />
3.3.2 Consumption <strong>in</strong> Belgium ............................................................................................................... 74<br />
3.3.3 Estimation of IG quantities to treat the ma<strong>in</strong> <strong>in</strong>dications ...................................................... 86<br />
3.3.4 Expected trends <strong>in</strong> consumption ................................................................................................ 97<br />
4 SELF SUFFICIENCY OF BELGIUM ............................................................................ 98<br />
4.1 WHAT ARE THE RISKS AT WORLDWIDE LEVEL ? ........................................................................ 98<br />
4.1.1 Plasma collection: Key role of the North American Region ................................................. 98<br />
4.1.2 Worldwide demand for plasma products / Focus on IVIG (2000-2008) .......................... 100<br />
4.1.3 Potential changes <strong>in</strong> demand structure .................................................................................... 100<br />
4.2 CONCEPT OF SELF SUFFICIENCY ..................................................................................................... 101<br />
4.2.1 In Belgium ....................................................................................................................................... 101<br />
4.2.2 In other countries ........................................................................................................................ 103<br />
4.3 HOW TO STAY OR BECOME SELF SUFFICIENT .......................................................................... 111<br />
4.3.1 Strategies to decrease IG use: lessons learned ...................................................................... 111<br />
4.3.2 Strategies to decrease IG use: what could be applied <strong>in</strong> Belgium ...................................... 115<br />
4.3.3 Increas<strong>in</strong>g the capacities of collect<strong>in</strong>g plasma ......................................................................... 115<br />
4.3.4 Transparency and better control of the supply of derivatives ........................................... 116<br />
4.4 CONCLUSIONS ....................................................................................................................................... 117<br />
5 APPENDICES ............................................................................................................... 118<br />
APPENDIX 1: ETHICAL DIMENSION OF DONATION: QUICK OVERVIEW .................................... 118<br />
APPENDIX 2 : SEARCH TERMS ........................................................................................................................ 120<br />
APPENDIX 3: GRADE CRITERIA FOR ASSIGNING GRADE OF EVIDENCE ...................................... 121<br />
APPENDIX 4: IMMUNO-HAEMATOLOGICAL SURVEY ........................................................................... 122<br />
APPENDIX 5: POTENTIAL CHANGES IN DEMAND VOLUME: FOCUS ON TWO EMERGING<br />
COUNTRIES .............................................................................................................................................. 124